1.55 USD
▲-0.01+1.31%
盘后 1.60 +4.35%
2026-08-03
市值
$93.50M
市盈率
—
EPS
-0.46
股息率
—
52 周区间
1.07 – 6.18
成交量
975.52K
Beta
1.15
目标价
6.60
52W 低 1.0752W 高 6.18
价格走势
公司简介
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical ...